GerardTKennealeyMD

Oncology • Wilmington, DE

Physician

Join to view full profile

Dr. Kennealey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kennealey's full profile

Already have an account?

Office
1308 Copley Dr
Suite 100
Wilmington, DE 19803
Phone+1 302-753-9225
Is this information wrong?

Education & Training

Yale-New Haven Medical CenterResidency, Internal Medicine, 1974 - 1975
Yale-New Haven Medical CenterResidency, Internal Medicine, 1970 - 1972
Yale School of MedicineClass of 1970

Certifications & Licensure

DE State Medical License 1987 - 2019

Clinical Trials

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer Start of enrollment: 2014 Feb 11
Terminated
Phase 2
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer Start of enrollment: 2014 May 01
Terminated
Phase 2
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) Start of enrollment: 2018 Mar 21
Terminated
Phase 1, Phase 2
A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) Start of enrollment: 2018 Oct 08
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

17 citations
A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non–Smal...
Giuseppe Giaccone, Rachel E. Sanborn, Saiama N. Waqar, Alex Martinez-Marti, Santiago Ponce, Huiling Zhen, Gerard Kennealey, Susan Erickson-Viitanen, Eric Schaefer> ;Clinical Lung Cancer. 2018 Sep 1
28 citations
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated...
Joyce O'Shaughnessy, Angela DeMichele, Cynthia X. Ma, Paul Richards, Denise A. Yardley, Gail S. Wright, Kevin Kalinsky, Ronald Steis, Sami Diab, Gerard Kennealey, Ryan...> ;Breast Cancer Research and Treatment. 2018 Apr 19
8 citations
Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with...
Kathryn S. Kolibaba, James A. Sterchele, Avani Joshi, Michael Forsyth, Erin Alwon, Hooman Beygi, Gerard T. Kennealey> ;Therapeutic Advances in Hematology. 2013 Feb 25
181 citations
Phase III Randomized Controlled Trial Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma Treated With Nolatrexed or Doxorubicin
Robert G. Gish, Camillo Porta, Lucian Lazar, Paul Ruff, Ronald Feld, Adina E. Croitoru, Lynn G. Feun, Krzysztof Jeziorski, John Charles Leighton, José Gallo, Gerard T....> ;Journal of Clinical Oncology. 2007 Jul 20
61 citations
Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
Gerald W. Chodak, Rooholloh Sharifi, Basil Kasimis, Norman L. Block, Effat MaCramalla, Gerard T. Kennealey> ;Urology. 1995 Dec 1
25 citations
Bicalutamide in the Treatment of Advanced Prostatic Carcinoma: A Phase II Noncomparative Multicenter Trial Evaluating Safety, Efficacy and Long-Term Endocrine Effects ...
Mark S. Soloway, Paul F. Schellhammer, Joseph A. Jr. Smith, Gerald W. Chodak, Nicholas J. Vogelzang, Gerard T. Kennealey> ;The Journal of Urology. 1995 Dec 1
105 citations
Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial
Nicholas J. Vogelzang, Gerald W. Chodak, Mark S. Soloway, Norman L. Block, Paul F. Schellhammer, Joseph A. Smith, Richard J. Caplan, Gerard T. Kennealey> ;Urology. 1995 Aug 1
34 citations
Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen
Haim Matzkin, Mark S. Soloway, Paul F. Schellhammer, Gerald Chodak, Joseph A. Smith, Richard Caplan, Gerard T. Kennealey> ;Cancer. 1993 Aug 15
23 citations
A comparison of Zoladex® and DES in the treatment of advanced prostate cancer: Results of a randomized, multicenter trial
Dennis L. Citrin, Martin I. Resnick, Patrick Guinan, Nazar Al‐Bussam, Mark Scott, Timothy C. Gau, Gerard T. Kennealey> ;The Prostate. 1991 Jan 1
161 citations
Patients' choice of treatment in stage D prostate cancer.
Barrie R. Cassileth, Edward James Seidmon, Mark S. Soloway, Howard I. Hait, Nicholas J. Vogelzang, Gerard T. Kennealey, Paul S. Schellhammer> ;Urology. 1989 May 1
22 citations
Combination chemotherapy for advanced breast cancer: two regimens containing adriamycin.
Gerard T. Kennealey, Barry Boston, Malcolm S. Mitchell, Mary Kathryn Knobf, Samuel N. Bobrow, John F. Pezzimenti, Roberta Lawrence> ;Cancer. 1978 Jul 1
9 citations
Sjögren's syndrome with pseudolymphoma 13 years after Hodgkin's disease.
Gerard T. Kennealey, Harvey W. Kaetz, G. J. Walker Smith> ;Archives of Internal Medicine. 1978 Apr 1
46 citations
Zoladex versus orchiectomy in treatmentof advanced prostate cancer: a randomized trial
Mark S. Soloway, Joseph A. Smith, Gerald W. Chodak, Mark Scott, Nicholas J. Vogelzang, Gerald T. Kennealey, Norman L. Block, Timothy C. Gau, Paul F. Schellhammer> ;Urology. 1991 Jan 1
''Tomudex'' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. ''Tomudex'' International Study Group.
Cunningham, D., Zalcberg, J., Smith, I., Gore, M., Pazdur, R., Burris, H., Meropol, N. J., Kennealey, G., Seymour, L.> ;Ann Oncol. 1996 Feb
Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.
Clarke, S. J., Hanwell, J., de Boer, M., Planting, A., Verweij, J., Walker, M., Smith, R., Jackman, A. L., Hughes, L. R., Harrap, K. R., Kennealey, G. T., Judson, I. R.> ;J Clin Oncol. 1996 May
14 citations
Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial.
Mark S. Soloway, Paul F. Schellhammer, Joseph A. Smith, Gerald W. Chodak, Gerald T. Kennealey> ;Urology. 1996 Jan 1
Cancer chemotherapeutic and biologic agents.
Kennealey, G. T.> ;CA Cancer J Clin. 1993 Mar 01
Re: A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia.
Strutt, K. L., Blackledge, G. R., Kennealey, G. T.> ;J Urol. 1994 May
72 citations
Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma.
Sharon D. Luikart, Gerald T. Kennealey, John M. Kirkwood> ;Journal of Clinical Oncology. 1984 Mar 1
Modification of response to histocompatibility antigens with chemotherapeutic agents.
Kennealey, G. T., Lytton, B., Ruddle, N., Mitchell, M. S.> ;Transplantation. 1971 Dec 01
48 citations
USE OF THE NONSTEROIDAL ANTI-ANDROGEN CASODEX IN ADVANCED PROSTATIC CARCINOMA
Gerard T. Kennealey, Barrington J.A. Furr> ;The Urologic Clinics of North America. 1991 Feb 1
Gonadotropin-releasing hormone and its analogues.
Kennealey, G. T., Milsted, R. A.> ;N Engl J Med. 1991 Aug 15
Recent developments in endocrine treatment of prostate cancer.
Vogelzang, N. J., Kennealey, G. T.> ;Cancer. 1992 Aug 15
109 citations
Quality of life and psychosocial status in stage D prostate cancer
B. R. Cassileth, Mark S. Soloway, Nicholas J. Vogelzang, J. M. Chou, P. D. Schellhammer, E. J. Seidmon, Gerald T. Kennealey> ;Quality of Life Research. 1992 Oct 1
Join now to see all

GerardTKennealeyMD

Dr. Kennealey is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.